H.C. Wainwright initiates Liquidia stock with buy rating
At a glance
- $LQDA today−0.69%last $55.98
- Vs industry peers+0.35 pts6-peer median −1.05% · in step
- Since Nov 13−3.48%from the first trade after the story
- 52-week range150.9% above low$22.31 – $93.61
- Last reported loss$236.3Mquarter to Sep 30, 2026 · 10-Q
- Coverage1 this week3 in 30 days · too few stories to call a pace
Nothing reported about liquidia across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stock is trading: $LQDA -0.69% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
Liquidia ($LQDA) slipped 0.69% to $55.98 in the latest session. Over the past month it is up 64.0%. It now sits 40% under the 52-week high of $93.61 and 151% above the year's low of $22.31. The year's high was 4.2 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $LQDA lost $236.3M over the quarter to Sep 30, 2026 on revenue of $225.3M (+31.2% QoQ). Operations brought in $279.9M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $248.9M. Total liabilities were $708.4M against $396.1M of cash on Sep 30, 2026. Liabilities of $708.4M exceeded assets of $682.9M on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Nov 10, 3 days before this story; it is $LQDA's own account and the first thing to read. Figures are as filed with the SEC; the $LQDA page has the full statements.
How much coverage it is getting
Wook has filed 3 stories on Liquidia in the last 30 days, 1 of them this week. That is a little busier than usual: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 3 neutral and 0 bearish. This one reads neutral too, in line with most of them. This is the only one from Investing.com; the rest came from other outlets.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $LQDA page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $LQDA: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 13, 2026. $LQDA has moved -3.48% ($58.00 to $55.98). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
